Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update

Keyphrases

• Bullous Pemphigoid 100%
• Controlled Experiment 12%
• Clinical Trials 12%
• Disease Severity 12%
• High Dose 12%
• Autoantibodies 12%
• Comorbidity 12%
• Treatment Options 12%
• Potential Treatments 12%
• Severe Cases 12%
• Adverse Effects 12%
• Immune Signaling 12%
• B Lymphocytes 12%
• Interleukin-4 (IL-4) 12%
• Anti-CD20 Antibody 12%
• Interleukin-17 (IL-17) 12%
• Interleukin-13 (IL-13) 12%
• Pruritus 12%
• Novel Therapies 12%
• Drug Exposure 12%
• Th2 Response 12%
• Improved Outcomes 12%
• Rituximab 12%
• Eosinophils 12%
• Immunoglobulin E Antibodies 12%
• Omalizumab 12%
• Cumulative Dose 12%
• Topical Therapy 12%
• Dupilumab 12%
• Junction Formation 12%
• Dosing Regimen 12%
• Complement Inhibitors 12%
• Safety Self-efficacy 12%
• Systemic Corticosteroids 12%
• Systemic Glucocorticoids 12%
• Interleukin-4 Receptor 12%
• BP180 12%
• Autoimmune Bullous Disease 12%
• BP230 12%
• Optimal Dosing 12%
• Dermal-epidermal Junction 12%
• Blister Formation 12%
• Chronic Use 12%
• IL-23 Inhibitors 12%
• Bullous Lesions 12%
• Tildrakizumab 12%
• Secukinumab 12%
• Novel Treatments 12%
• Rising Incidence 12%
• Janus Kinase Inhibitors 12%
• Increasing Life Expectancy 12%
• Corticosteroid Tapering 12%
• Efgartigimod 12%
• Neonatal Fc Receptor Antagonist 12%
• Nomacopan 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Bullous Pemphigoid 100%
• Diseases 25%
• Clinical Trial 12%
• Controlled Clinical Trial 12%
• Glucocorticoid 12%
• Disease Severity 12%
• Immunoglobulin E Antibody 12%
• Pruritus 12%
• Interleukin 4 12%
• Fc Receptor 12%
• Dupilumab 12%
• Rituximab 12%
• Life Expectancy 12%
• Interleukin 23 12%
• Complement Inhibitor 12%
• Nomacopan 12%
• Blister 12%
• Interleukin 4 Receptor 12%
• Vesicular Rash 12%
• Bertilimumab 12%
• Tildrakizumab 12%
• Monoclonal Antibody 12%
• Receptor Antagonist 12%
• Omalizumab 12%
• Autoantibodies 12%
• Interleukin 13 12%
• Interleukin 17 12%
• Janus Kinase Inhibitor 12%
• Secukinumab 12%
• Clobetasol Propionate 12%
• Comorbidity 12%

Immunology and Microbiology

• Bullous Pemphigoid 100%
• Autoantibodies 12%
• B Cell 12%
• Autoimmunity 12%
• Nomacopan 12%
• Neonatal Fc Receptor 12%
• Interleukin-4 Receptor 12%
• Dermoepidermal Junction 12%
• Tildrakizumab 12%
• Bertilimumab 12%
• Immunoglobulin E Antibody 12%
• Monoclonal Antibody 12%
• Interleukin 23 12%
• Drug Megadose 12%
• CD20 12%
• Interleukin 13 12%
• Drug Exposure 12%
• Omalizumab 12%
• Rituximab 12%
• Dupilumab 12%
• Life Expectancy 12%
• Complement Inhibitor 12%
• Secukinumab 12%
• Interleukin 4 12%
• Eosinophil 12%
• Comorbidity 12%
• Interleukin 17 12%
• Glucocorticoid 12%